Package Leaflet: Information for the Patient
Paliperidone TAD3 mg prolonged-release tablets EFG
Paliperidone TAD6 mg prolonged-release tablets EFG
Paliperidone TAD9 mg prolonged-release tablets EFG
Read the entire package leaflet carefully before starting to take this medication, as it contains important information for you.
Contents of the package leaflet:
Paliperidone contains the active substance paliperidone, which belongs to the class of antipsychotic medications.
Paliperidone is used to treat schizophrenia in adults and adolescents aged 15 years and older.
Schizophrenia is a disorder that causes symptoms such as hearing, seeing, or feeling things that do not exist, having false beliefs, being abnormally suspicious, withdrawing into oneself, speaking incoherently, and flattening of behavior and emotions. People with this disorder may also feel depressed, anxious, guilty, or tense.
Paliperidone is also used to treat schizoaffective disorder in adults.
Schizoaffective disorder is a mental condition in which the person experiences several of the symptoms of schizophrenia (listed in the previous paragraph) in addition to symptoms of mood disorder (feeling euphoric, sad, agitated, distracted, insomnia, talkativeness, loss of interest in daily activities, excessive or insufficient sleep, excessive or insufficient food intake, and recurring thoughts of suicide).
Paliperidone can help alleviate the symptoms of your illness and prevent them from recurring.
Do not takepaliperidone
Warnings andprecautions
Consult your doctor or pharmacist before starting to take paliperidone.
If you have any of these diseases, please consult your doctor, as it may be necessary to adjust your dose or keep you under observation for a while.
Because it has been rarely observed in patients treated with paliperidone that they have a dangerously low number of a type of white blood cells necessary to fight infections in the blood, your doctor may check the number of white blood cells.
Paliperidone may cause you to gain weight. Significant weight gain can negatively affect your health. Your doctor will regularly monitor your weight.
In patients treated with paliperidone, diabetes mellitus or worsening of pre-existing diabetes mellitus has been observed, and your doctor should check for signs of increased blood sugar. In patients with pre-existing diabetes mellitus, blood sugar should be regularly monitored.
During eye surgery for cataracts, the pupil (the black circle in the middle of the eye) may not increase in size as needed. Additionally, the iris (the colored part of the eye) may become flaccid during surgery, which can cause eye damage. If you are considering eye surgery, make sure to inform your ophthalmologist that you are using this medication.
Children andadolescentes
Paliperidone should not be administered to children and adolescents under 15 years of age for the treatment of schizophrenia.
Paliperidone should not be administered to children and adolescents under 18 years of age for the treatment of schizoaffective disorder.
This is because it is unknown whether paliperidone is safe or effective in this age group.
Other medications and paliperidone
Tell your doctor or pharmacist if you are using, have recently used, or may need to use any other medication.
Abnormalities in heart function may appear when taking this medication with other medications for heart rhythm control or other medications such as antihistamines, antimalarials, or antipsychotics.
Since this medication acts primarily on the brain, it may interfere with other medications (or alcohol) that also act on it, due to the sum of effects on brain function.
This medication may reduce blood pressure, so you should be careful if you take this medication with other medications that also reduce it.
This medication may reduce the effect of medications for Parkinson's disease and restless legs syndrome (e.g., levodopa).
The effects of this medication may be affected if you take medications that influence the speed of intestinal movement (e.g., metoclopramide).
A reduction in the dose of this medication should be considered when administered with valproate.
The use of oral risperidone with this medication is not recommended, as this combination may cause an increase in side effects.
Paliperidone TAD should be used with caution with medications that increase the activity of the central nervous system (psychostimulants such as methylphenidate).
Taking paliperidone withalcohol
You should avoid consuming alcohol during treatment with this medication.
Pregnancy andlactation
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medication.
You should not take this medication during pregnancy unless you have discussed it with your doctor.
The following symptoms may occur in newborns of mothers who have been treated with paliperidone in the last trimester of pregnancy (last three months of pregnancy): tremors, stiffness and/or muscle weakness, drowsiness, agitation, breathing problems, and difficulty feeding. If your baby develops any of these symptoms, you should contact your doctor.
You should not breastfeed while taking this medication.
Driving and usingmachines
During treatment with this medication, dizziness and vision problems may occur (see section 4, possible side effects). This should be taken into account when maximum attention is required, for example, when driving or operating machinery.
Paliperidone TAD contains sodium
This medication contains less than 23 mg of sodium (1 mmol) per tablet; this is, essentially "sodium-free".
Follow the administration instructions for this medication exactly as indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.
Use inadults
The recommended dose in adults is 6 mg once daily in the morning. Your doctor may increase or decrease it within the dosage range of 3 mg to 12 mg once daily in the case of schizophrenia or 6 mg to 12 mg once daily in the case of schizoaffective disorder. This depends on how well the medication works for you.
Use inadolescentes
The recommended starting dose for the treatment of schizophrenia in adolescents aged 15 years and older is 3 mg once daily in the morning.
For adolescents who weigh 51 kg or more, the dose may be increased within the range of 6 mg to 12 mg once daily.
For adolescents who weigh less than 51 kg, the dose may be increased to 6 mg once daily.
Your doctor will decide how much to administer. The amount you take depends on how well the medication works for you.
How and when to take paliperidone
This medication should be taken orally, swallowed whole with water or other liquids. It should not be chewed, broken, or crushed.
This medication should be taken in the morning with breakfast or on an empty stomach, but each day in the same way. Do not alternate between taking the medication one day with breakfast and the next day on an empty stomach.
The active substance, paliperidone, dissolves once swallowed, and the tablet coating is eliminated from the body through the feces.
Patient with kidney problems
Your doctor may adjust the dose of this medication according to your renal function.
Elderly patients
Your doctor may reduce your dose of medication if your renal function is reduced.
If you take more paliperidone than you should
In case of overdose or accidental ingestion, consult your doctor, pharmacist, or go to the nearest hospital immediately, or call the Toxicology Information Service. Phone: 91 562 04 20, indicating the medication and the amount ingested. You may experience drowsiness, fatigue, abnormal body movements, problems standing and walking, dizziness due to decreased blood pressure, and alterations in heartbeats.
If you forget to take paliperidone
Do not take a double dose to make up for forgotten doses. If you forget a dose, take the next dose the following day. If you forget two or more doses, contact your doctor.
If you stop treatment with paliperidone
Do not stop taking this medication, as you will lose the effects of the medication. You should not stop taking this medication unless your doctor tells you to, as your symptoms may return.
If you have any other questions about the use of this medication, ask your doctor or nurse.
Like all medicines, this medicine can cause adverse effects, although not all people suffer from them.
Report immediately to your doctorif:
Very common adverse effects: may affect more than 1 in 10 patients
Common adverse effects: may affect up to 1 in 10 patients
Uncommon adverse effects: may affect up to 1 in 100 patients
Rare adverse effects: may affect up to 1 in 1,000 patients
Unknown frequency: cannot be estimated from available data
The following adverse effects have appeared with the use of another medicine called risperidone that is very similar to paliperidone, so it is also expected to appear with paliperidone: sleep-related eating disorder, other types of cerebral vascular problems, lung crackling sounds, and severe or fatal skin rash with blisters and peeling that can start inside and around the mouth, nose, eyes, and genitals and spread to other areas of the body (Stevens-Johnson syndrome/toxic epidermal necrolysis). Eye problems may also occur during cataract surgery. During cataract surgery, a condition called intraoperative floppy iris syndrome (IFIS) may occur if you are taking or have taken paliperidone. If you need to undergo cataract surgery, make sure to inform your ophthalmologist if you are taking or have taken this medication.
Additional adverse effects in adolescents
Adolescents generally presented similar adverse effects to those found in adults, except for the following adverse effects that were detected more frequently:
Reporting of adverse effects
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect that does not appear in this leaflet. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaram.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiration date that appears on the packaging after CAD. The expiration date is the last day of the month indicated.
Store in the original packaging to protect it from moisture.
This medicine does not require any special storage temperature.
Medicines should not be thrown away through the sewers or in the trash. Deposit the packaging and medicines that you no longer need in the SIGRE Point of the pharmacy. Ask your pharmacist how to dispose of the packaging and medicines that you no longer need. This way, you will help protect the environment.
Composition of Paliperidona TAD
Core: macrogol 200,000, macrogol 7,000,000, macrogol 4000, hydroxybutyltoluene, povidone, sodium chloride, microcrystalline cellulose, magnesium stearate, red iron oxide (E172), hydroxypropylcellulose, and cellulose acetate.
Coating: hypromellose, titanium dioxide (E171), talc, propylene glycol, yellow iron oxide (E172) - only for 6 mg tablets, and red iron oxide (E172) - only for 9 mg tablets.
Printed ink: shellac, black iron oxide (E172), and propylene glycol. See section 2 "Paliperidona TAD contains sodium".
Appearance of the product and package contents
3 mg: Film-coated tablets, biconvex, round, white to grayish-white in color with a possible irregular surface and printed with the mark P3 on one side of the tablet. Diameter: approximately 9 mm.
6 mg: Film-coated tablets, biconvex, round, yellowish-brown in color with a possible irregular surface and printed with the mark P6 on one side of the tablet. Diameter: approximately 9 mm.
9 mg: Film-coated tablets, biconvex, round, light pink in color with a possible irregular surface and printed with the mark P9 on one side of the tablet. Diameter: approximately 9 mm.
Paliperidona TAD is available in packages of 14x1, 28x1, and 56x1 prolonged-release tablets in unit-dose blisters.
Only some package sizes may be marketed.
Marketing authorization holder
TAD Pharma GmbH, Heinz-Lohmann-Straße 5, 27472 Cuxhaven, Germany
Manufacturer
KRKA d.d. Novo mesto
Smarjeska cesta 6
8501 Novo mesto
Slovenia
You can request more information about this medicine by contacting the local representative of the marketing authorization holder:
KRKA Farmacéutica, S.L., C/ Anabel Segura 10, 28108 Alcobendas, Madrid, Spain
This medicine is authorized in the member states of the European Economic Area with the following names:
Member state name | Medicine name |
Hungary | Paliperidon Krka 3 mg retard tablet Paliperidon Krka 6 mg retard tablet Paliperidon Krka 9 mg retard tablet |
Belgium | Paliperidon Krka 3 mg tablets with prolonged release Paliperidon Krka 6 mg tablets with prolonged release Paliperidon Krka 9 mg tablets with prolonged release |
Cyprus | Paliperidon TAD |
Denmark | Paliperidon Krka |
Spain | Paliperidona TAD 3 mg prolonged-release tablets EFG Paliperidona TAD 6 mg prolonged-release tablets EFG Paliperidona TAD 9 mg prolonged-release tablets EFG |
Iceland | Paliperidon Krka 3 mg prolonged-release tablets Paliperidon Krka 6 mg prolonged-release tablets Paliperidon Krka 9 mg prolonged-release tablets |
Italy | Paliperidone Krka |
Ireland | Paliperidon TAD |
Sweden | Paliperidon Krka 3 mg depot tablets Paliperidon Krka 6 mg depot tablets Paliperidon Krka 9 mg depot tablets |
Date of the last revision of this leaflet:April 2024
Detailed information about this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/
The average price of PALIPERIDONE TAD 6 mg PROLONGED-RELEASE TABLETS in October, 2025 is around 55.17 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.